An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Breast Cancer Based on FDA Adverse Event ReportingSystem Data
Targeted therapies of lapatinib, fulvestrant, and endocrine agents (letrozole or ribociclib) show disproportionately high AE reporting odds ratios, necessitating vigilant monitoring. HER2-positive BC treatments (trastuzumab) and TNBC agents (sonidegib) exhibit distinct risk profiles, advocating for personalized risk-benefit assessments for BC patients.
Authors
- Wenqing Cao (ORCID: https://orcid.org/0000-0002-2761-3355)
- Shanzheng Chen
- Xinyu Liu
- Chengyu Wang (ORCID: https://orcid.org/0000-0003-2384-0822)
- Na Jin (ORCID: https://orcid.org/0009-0000-7700-4702)
- Ziran Qiu
- Jun Yang
- Chunhua Ye
- Yuan Chen
- Xiaoqin Yao
- Zhong Li
- Rui Li
Institutions
- Loudi Central Hospital (CN)
Publication Details
- Journal
- Current Medicinal Chemistry
- Published
- 2026-01-07
- DOI
- https://doi.org/10.2174/0109298673376219251029174252
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00